Deschloroclozapine, a metabolite of Clozapine, is a highly potent muscarinic DREADDs agonist. Deschloroclozapine binds to DREADD receptor subtypes hM3Dq and hM4Di with K i of 6.3 and 4.2 nM, respectively. [ 11 C]-Deschloroclozapine is developed as a promising PET tracer for DREADD imaging In Vitro Designer Receptors Exclusively Activated by Designer Drugs (DREADD) are a chemogenetic approach for remote manipulation of neuronal activity in freely-moving animals. DREADDs comprise mutated G protein-coupled receptors (GPCRs) that do not respond to their endogenous neurotransmitter, but do respond to an otherwise “inert” exogenous substance. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Deschloroclozapine (0.3?mg/kg; intramuscularly) impairs working memory function in male rhesus macaques (aged between 5 and 6 years and weighing 5.5-7.9?kg). ?\nDeschloroclozapine (0.1?mg/kg; i.m) is effective at activating DREADD receptors in vivo and reversibly inducing behavioral effects in monkeys. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:mAChR3 mAChR4